Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049)
2.020
-0.040 (-1.94%)
At close: Feb 13, 2026
HKG:8049 Revenue
Jilin Province Huinan Changlong Bio-pharmacy Company had revenue of 438.87M CNY in the half year ending June 30, 2025, with 10.93% growth. This brings the company's revenue in the last twelve months to 926.93M, up 10.48% year-over-year. In the year 2024, Jilin Province Huinan Changlong Bio-pharmacy Company had annual revenue of 881.16M with 4.71% growth.
Revenue (ttm)
926.93M CNY
Revenue Growth
+10.48%
P/S Ratio
1.11
Revenue / Employee
1.16M CNY
Employees
798
Market Cap
1.13B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 881.16M | 39.61M | 4.71% |
| Dec 31, 2023 | 841.55M | -41.00K | - |
| Dec 31, 2022 | 841.59M | 136.13M | 19.30% |
| Dec 31, 2021 | 705.46M | 83.21M | 13.37% |
| Dec 31, 2020 | 622.25M | -23.64M | -3.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chia Tai Enterprises International | 4.42B |
| Zhongzhi Pharmaceutical Holdings | 2.20B |
| Essex Bio-Technology | 1.72B |
| Jacobson Pharma Corporation | 1.53B |
| Lee's Pharmaceutical Holdings | 1.44B |
| Dawnrays Pharmaceutical (Holdings) | 1.22B |
| Golden Throat Holdings Group Company | 1.07B |
| JBM (Healthcare) | 812.98M |